Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma

Journal article

Metastatic disease from uveal melanoma occurs in almost 50% of patients suffering from this ocular tumour, with median survival from development of symptoms being around 1 year. In contrast to cutaneous melanoma, kinase inhibitors and immune checkpoint inhibitors are usually ineffective in patients with metastatic uveal melanoma. Tebentafusp is a novel form of immunotherapy based on the immune-mobilising monoclonal T cell receptor against cancer (ImmTAC) platform, which comprises a soluble T cell receptor that is fused to an anti-CD3 single-chain variable fragment. The T cell receptor domain of tebentafusp targets cells present a human leukocyte antigen-A*02:01 complexed with a peptide derived from the melanoma-associated antigen gp100, which is expressed strongly by melanoma cells, weakly by normal melanocytes and minimally by other tissues. The anti-CD3 domain recruits CD3+ T cells (and, indirectly, other immune cells), redirecting these to the melanoma cells. The most common adverse events with tebentafusp are manageable and usually transient. Early survival data in patients with metastatic uveal melanoma are promising when considered alongside historical data. Based on these encouraging results, a randomised study comparing tebentafusp to investigator’s choice of therapy in metastatic uveal melanoma is ongoing.

Authors: Damato, BE; Dukes, J; Goodall, H; Carvajal, RD

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: MDPI
• Journal: Cancers
• Volume: 11
• Issue: 7
• Article number: 971
• Publication date: 2019-07-11
• Acceptance date: 2019-07-08
• DOI: 10.3390/cancers11070971
• EISSN: 2072-6694
• ISSN: 2072-6694
• Keywords: tebentafusp; T cell receptor; metastatic uveal melanoma; ImmTAC platform; anti-CD3 bispecific; immunotherapy; clinical data; preclinical data; T cell